J. Locklear

发表

Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER*

K. Järbrink, M. Knapp, J. Locklear, 2009, Current medical research and opinion.

Different Approaches To Valuing the Lost Productivity of Patients with Migraine

K. Frick, J. Lofland, J. Locklear, 2012, PharmacoEconomics.

Clinicoeconomics and Outcomes Research Dovepress Economic and Humanistic Burden of Illness in Generalized Anxiety Disorder: an Analysis of Patient Survey Data in Europe

K. Järbrink, M. Dibonaventura, S. Toghanian, 2022 .

Effect of extended-release quetiapine fumarate on quality of life and sleep in elderly patients with generalized anxiety disorder

J. Endicott, H. Svedsäter, C. Datto, 2013 .

Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder

J. Endicott, H. Svedsäter, J. Locklear, 2012, Neuropsychiatric disease and treatment.

Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data.

B. Alemayehu, S. Chavoshi, W. Earley, 2013, Clinical therapeutics.

Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia

K. Järbrink, Á. Benedict, N. Kreif, 2009 .

Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population.

M. Eaddy, A. Grogg, J. Locklear, 2005, Clinical therapeutics.

PMH71 The Impact of Once-Daily Extended-Release Quetiapine Fumarate (Quetiapine XR) on Length and Costs of Hospitalisation of Patients with Schizophrenia or Bipolar Disorder

P. Wahlqvist, H. Eriksson, U. Gustafsson, 2011 .

PMH72 The Impact of Once-Daily Extended-Release Quetiapine Fumarate (Quetiapine XR) on Length of Hospitalisation of Patients with Acute Bipolar Mania

P. Wahlqvist, M. Bonafede, H. Eriksson, 2011 .

Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode

M. Ekman, G. Meier, P. Lindgren, 2012, PharmacoEconomics.

Assessing health-related quality of life in generalized anxiety disorder using the Quality Of Life Enjoyment and Satisfaction Questionnaire

J. Endicott, D. Revicki, K. Wyrwich, 2009, International clinical psychopharmacology.

Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate

R. McIntyre, A. Clayton, H. Svedsäter, 2013, CNS Spectrums.

Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia.

P. Weiden, C. Kozma, A. Grogg, 2004, Psychiatric services.

Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA

R. Diamond, M. Rupnow, J. Locklear, 2012, PharmacoEconomics.

A systematic review of the evidence of the burden of bipolar disorder in Europe

J. Priaulx, J. Locklear, A. Heyes, 2009, Clinical practice and epidemiology in mental health : CP & EMH.

Impact of once-daily extended-release quetiapine fumarate on hospitalization length in patients with acute bipolar mania.

P. Wahlqvist, M. Bonafede, H. Eriksson, 2015, Journal of comparative effectiveness research.

Cost and Utilization Patterns of Fentanyl Transdermal System and Oxycodone Hydrochloride Controlled- Release in a California Medicaid Population

M. Ashburn, J. Schein, J. Malkin, 2015 .

Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder

S. Montgomery, H. Svedsäter, H. Eriksson, 2014, International clinical psychopharmacology.

Development and content validity of a patient reported outcomes measure to assess symptoms of major depressive disorder

J. Endicott, K. Lasch, Marcy Fitz-Randolph, 2012, BMC Psychiatry.

Content validity of the Sheehan Irritability Scale in patients with major depressive disorder

D. Sheehan, G. Dunbar, D. Revicki, 2016, International clinical psychopharmacology.

Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials.

E. Vieta, M. Ekman, M. Åström, 2011, The international journal of neuropsychopharmacology.

Assessment of Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form responder thresholds in generalized anxiety disorder and bipolar disorder studies

J. Endicott, D. Revicki, K. Wyrwich, 2011, International clinical psychopharmacology.

Treatment Options for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials

E. Vieta, M. Ekman, M. Åström, 2010, Journal of clinical psychopharmacology.

Humanistic and economic burden of generalized anxiety disorder in North America and Europe.

D. Sheehan, D. Revicki, K. Wyrwich, 2012, Journal of affective disorders.

Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study.

D. Sheehan, H. Svedsäter, H. Eriksson, 2013, Journal of affective disorders.

Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy

M. Trivedi, M. Thase, M. Bauer, 2013, International clinical psychopharmacology.

The Measurement of Health-Related Quality of Life in a Population with Generalized Anxiety Disorder – Findings from the QUEST Study

J. Endicott, D. Revicki, K. Wyrwich, 2011 .

Effects of once-daily extended release quetiapine fumarate (quetiapine XR) on quality of life and sleep in elderly patients with major depressive disorder.

J. Endicott, H. Svedsäter, C. Datto, 2013, Journal of affective disorders.

Impact of extended-release quetiapine fumarate on hospitalization length and cost in schizophrenia and bipolar disorder patients: a retrospective, hospital-based, US-cohort analysis.

P. Wahlqvist, H. Eriksson, U. Gustafsson, 2014, Journal of comparative effectiveness research.

Understanding the relationships between health outcomes in generalized anxiety disorder clinical trials

D. Revicki, K. Wyrwich, H. Svedsäter, 2011, Quality of Life Research.

Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate

D. Sheehan, H. Svedsäter, C. Datto, 2012, International clinical psychopharmacology.

Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials.

E. Vieta, M. Ekman, M. Åström, 2011, The international journal of neuropsychopharmacology.

Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective

H. Volz, M. Jaeger, J. Locklear, 2008, Current medical research and opinion.

Clinicoeconomics and Outcomes Research Dovepress Economic and Humanistic Burden of Illness in Generalized Anxiety Disorder: an Analysis of Patient Survey Data in Europe

K. Järbrink, M. Dibonaventura, S. Toghanian, 2022 .

Clinical Practice and Epidemiology in Mental Health a Systematic Review of the Evidence of the Burden of Bipolar Disorder in Europe

J. Priaulx, J. Locklear, A. Heyes, 2008 .

Using a Panel Survey to Identify Predictors of Disease-Modifying Drug Adherence in Patients with Multiple Sclerosis.

C. Kozma, A. Phillips, J. Locklear, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis.

S. Liu, J. Locklear, B. Paulsson, 2009, Clinical therapeutics.